Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 21 May 2026
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC